Allergies News and Research

Latest Allergies News and Research

Ivermectin is ineffective in non-severe COVID-19 patients according to new study

A new study evaluated the effect of ivermectin on time to recovery from coronavirus disease 2019 (COVID-19) in patients with mild to moderate disease.

25 Oct 2022

Many children live in homes with leftover prescription medications, poll suggests

Many children live in homes with unused prescription drugs and expired medications, a new national poll suggests.

25 Oct 2022

Scientists use systems biology approach to identify molecular players in rheumatoid arthritis

Using a novel systems biology approach, scientists at University of California San Diego School of Medicine have further parsed the cellular players and roles involved in rheumatoid arthritis (RA), a complex disease that affects more than one million Americans in ways that have defied development of uniform treatments.

24 Oct 2022

Viral shedding rate declines rapidly during the first year among people with HSV-1 genital infections

People with a genital infection of the herpes simplex virus type 1 (HSV-1), which usually causes cold sores, frequently shed the virus in the first months after infection, raising the risk that they might spread the virus to sexual partners during this time.

24 Oct 2022

CDC Director signs decision memo allowing Novavax monovalent COVID-19 boosters for adults

Today, CDC's Director Rochelle P. Walensky, M.D., M.P.H., signed a decision memo allowing Novavax monovalent COVID-19 boosters for adults.

24 Oct 2022

Dog ownership during infancy might attenuate the risk of persistent wheezing

In a new study, researchers examined the gene-environment (GxE) interactions between pet ownership in infancy and the 17q12-21 (asthma-risk) locus concerning wheezing.

24 Oct 2022

Three-dose regimen of HEPLISAV-B vaccine fully protects people living with HIV, data shows

The AIDS Clinical Trials Group (ACTG), the world's largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, today presented a session demonstrating that a three-dose regimen of the HEPLISAV-B vaccine fully protected people living with HIV at IDWeek 2022, taking place in Washington D.C. from October 19-22, 2022.

20 Oct 2022

Three-dose course of the hepatitis B vaccine fully protects adults living with HIV

A three-dose course of the hepatitis B vaccine HEPLISAV-B fully protected adults living with HIV who had never been vaccinated against or infected with the hepatitis B virus (HBV), according to study findings presented today at the IDWeek conference in Washington, D.C.

20 Oct 2022

Mass General Brigham sites announce participation in phase 3 trial of monkeypox treatment

Massachusetts General Hospital and Brigham and Women's Hospital, the founding members of Mass General Brigham, today announced their participation in STOMP (Study of Tecovirimat for Human Monkeypox Virus), a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat (TPOXX) for the treatment of human monkeypox.

19 Oct 2022

Does skin inflammation exacerbate COVID-19?

In a new study, researchers discussed inflammation during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Oct 2022

Danish researchers take an important step in finding a cure for HIV

For around 40 years, scientists all over the world have been unsuccessfully trying to find a cure for HIV, but now a team of researchers from Aarhus University and Aarhus University Hospital have apparently found an important element in the equation.

17 Oct 2022

Study links chemical composition of fine particulate air pollution to worse lung disease outcomes

People with a disease characterized by lung scarring that has no obvious cause are more likely to die if they live in areas with higher levels of air pollution composed of chemicals associated with industrial sources and vehicular traffic, according to new research led by University of Pittsburgh scientists.

17 Oct 2022

Selective immunoglobulin A deficiency a risk factor for severe COVID-19

In a recent study published in The Journal of Allergy and Clinical Immunology, researchers in New Zealand gathered evidence to show that selective immunoglobulin A deficiency (sIgAD) is an understated risk factor for severe coronavirus disease 2019 (COVID-19).

17 Oct 2022

Allergies News and Research

Latest Allergies News and Research

Ivermectin is ineffective in non-severe COVID-19 patients according to new study

Many children live in homes with leftover prescription medications, poll suggests

Scientists use systems biology approach to identify molecular players in rheumatoid arthritis

Viral shedding rate declines rapidly during the first year among people with HSV-1 genital infections

CDC Director signs decision memo allowing Novavax monovalent COVID-19 boosters for adults

Dog ownership during infancy might attenuate the risk of persistent wheezing

Three-dose regimen of HEPLISAV-B vaccine fully protects people living with HIV, data shows

Three-dose course of the hepatitis B vaccine fully protects adults living with HIV

Mass General Brigham sites announce participation in phase 3 trial of monkeypox treatment

Does skin inflammation exacerbate COVID-19?

Danish researchers take an important step in finding a cure for HIV

Study links chemical composition of fine particulate air pollution to worse lung disease outcomes

Selective immunoglobulin A deficiency a risk factor for severe COVID-19

Advances in nasal delivery of antibiotics

Study illuminates how pain neurons protect the gut from damage

Study reveals why viral infections are less frequent but more severe in individuals with Down syndrome

HIV patients with moderate immune suppression at greater risk of severe COVID-19 "breakthrough" infection

Clinical trial to evaluate antiviral drug for monkeypox begins in the Democratic Republic of the Congo

Clinical trial to test the safety, efficacy of bacteriophages for treating P. aeruginosa infections in CF patients

Cat allergen immunotherapy works better and more quickly when combined with monoclonal antibody

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Allergies News and Research

Latest Allergies News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in